SHARE Study Helps Identify a Genetic Variant Associated with Statin Use and Muscle Pain
A University of Dundee study, led by SHARE Director Professor Colin Palmer, has found that some people are genetically predisposed to suffering muscular aches and pains when taking statins, and therefore may stop taking their medication. As statins are prescribed to lower cholesterol levels, individuals are put at a higher risk of developing diseases of the heart and blood vessels, which the statins had been prescribed to prevent.
The study found that there is a common variant in a gene that predisposes people to developing muscle aches, regardless of whether they are taking statins. However, it is also found that there is a genetic sub-group of people who have a higher risk of statin-induced muscle aches.
This opens up the possibility for screening to identify those who are most likely to have an adverse reaction to statins and who could be prescribed an alternative drug. Those genetically predisposed to muscle aches could be forewarned about the possibility of developing symptoms and be closely monitored.
Professor Palmer said, "We found that there are people in the general population who carry a genetic factor that predisposes them to muscle aches. If these people are put on statins, they may discontinue their medication in the erroneous belief that it is the statin that is making their muscles ache. At the same time, we observed that there is a genetic sub-group of patients who are susceptible to statin-specific muscle aches.
"This means that it would be possible to test prospective statin users for key genetic variants, including LILRB5, to prevent people being put on statins if they are likely to have an adverse reaction to them. Adverse reactions are a major reason for patients stopping taking medication, which puts the patient at an increased risk of a cardiovascular event. This is the first time that a genetic variant thought to be involved in the repair and regeneration of muscles has been found to be associated with this side effect."
Dr Moneeza Siddiqui, who is the first author of the study, said "We have a strong hypothesis for the involvement of our gene in the process of muscle repair and recovery. We know that the immune system is involved in the repair and regeneration of muscles and that our gene (LILRB5) is involved in the immune system, and may control the expression of a key factor called Foxp3, that enables the mechanism by which the immune system repairs muscle cells."
Statins are the first choice for doctors who need to lower cholesterol in patients to prevent or treat heart and blood vessel diseases. However, reports of users complaining of muscle aches and stopping their medication range from 7 to 29%.
For people who cannot tolerate statins, alternative treatments include ezetimibe and a new class of drugs calles PCSK9-inhibitors. Further work needs to be done to confirm exactly how the genetic variant is involved in the repair of muscles.
This research was helped by the 175,000 people around Scotland who have signed up to SHARE to help medical research. To register for SHARE then please click here.